Among the 3209 patients treated with GLE/PIB, 21 patients were excluded because of documented decompensated cirrhosis at baseline (12 patients) or previous exposure to NS3/4A protease inhibitor and/or NS5A inhibitor-containing DAAs (9 patients), in accordance with the Taiwan Food and Drug Administration (TFDA)-approved label. The gene discussed is KRAS; the disease is Cirrhosis.